1. Home
  2. NAMS vs ENLT Comparison

NAMS vs ENLT Comparison

Compare NAMS & ENLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • ENLT
  • Stock Information
  • Founded
  • NAMS 2019
  • ENLT 2008
  • Country
  • NAMS Netherlands
  • ENLT Israel
  • Employees
  • NAMS N/A
  • ENLT N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • ENLT
  • Sector
  • NAMS Health Care
  • ENLT
  • Exchange
  • NAMS Nasdaq
  • ENLT Nasdaq
  • Market Cap
  • NAMS 2.5B
  • ENLT 2.0B
  • IPO Year
  • NAMS N/A
  • ENLT 2023
  • Fundamental
  • Price
  • NAMS $18.96
  • ENLT $25.35
  • Analyst Decision
  • NAMS Strong Buy
  • ENLT Buy
  • Analyst Count
  • NAMS 8
  • ENLT 3
  • Target Price
  • NAMS $42.88
  • ENLT $19.67
  • AVG Volume (30 Days)
  • NAMS 1.0M
  • ENLT 40.6K
  • Earning Date
  • NAMS 08-06-2025
  • ENLT 08-06-2025
  • Dividend Yield
  • NAMS N/A
  • ENLT N/A
  • EPS Growth
  • NAMS N/A
  • ENLT 90.47
  • EPS
  • NAMS N/A
  • ENLT 0.98
  • Revenue
  • NAMS $47,140,000.00
  • ENLT $397,296,000.00
  • Revenue This Year
  • NAMS N/A
  • ENLT $355.90
  • Revenue Next Year
  • NAMS N/A
  • ENLT $42.83
  • P/E Ratio
  • NAMS N/A
  • ENLT $25.98
  • Revenue Growth
  • NAMS 586.97
  • ENLT 44.42
  • 52 Week Low
  • NAMS $14.06
  • ENLT $14.01
  • 52 Week High
  • NAMS $27.29
  • ENLT $25.89
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 51.31
  • ENLT 78.70
  • Support Level
  • NAMS $17.97
  • ENLT $22.61
  • Resistance Level
  • NAMS $18.97
  • ENLT $23.72
  • Average True Range (ATR)
  • NAMS 1.12
  • ENLT 0.52
  • MACD
  • NAMS -0.09
  • ENLT 0.34
  • Stochastic Oscillator
  • NAMS 31.07
  • ENLT 92.89

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About ENLT Enlight Renewable Energy Ltd.

Enlight Renewable Energy Ltd develops, finances, constructs, owns, and operates utility-scale renewable energy projects. The company's operating segments are the MENA segment, Europe segment, U.S.A segment, and Others. It generates the majority of its revenue from the Europe segment, which produces its revenue from the sale of the electricity that is produced through wind energy and solar energy in Europe.

Share on Social Networks: